Kancera AB, a biotechnology company, engages in the development and sale of drug candidates that cure or stop the progression of cancer. The company develops drugs for the treatment of leukemia and solid tumors, based on blocking survival signals in the cancer cell and on addressing cancer metabolism. Its pharmaceutical development projects include ROR inhibitors, which are drug candidate for treatment of leukemia and solid tumors; and PFKFB inhibitors for reducing cancer’s energy supply, as well as epigenetic pharmaceutical development targeting cancer and parasitic diseases. The company was founded in 2010 and is based in Solna, Sweden.
kancera ab (KAN:Stockholm)
Karolinska Institutet Science Park
Solna, 171 48
Phone: 46 8 50 12 60 80
|No competitor information is available for KAN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact KANCERA AB, please visit www.kancera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.